

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

GRANT OF SHARE OPTIONS

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of LifeTech Scientific Corporation (the “**Company**”) hereby announces that the Board has resolved to grant 35,000,000 share options (the “**Share Options**” and each a “**Share Option**”) to subscribe for a total of 35,000,000 ordinary shares with nominal value of US\$0.00000125 each (“**Shares**” and each a “**Share**”) in the share capital of the Company to 35 eligible participants (the “**Grantees**”), who are employees or consultants of the Group subject to acceptances of the Grantees, under the Company’s share option scheme adopted on 17 September 2021. Such Shares represent approximately 0.76% of the issued share capital of the Company as at the date of this announcement.

Details of the Share Options are set out as follows:

Date of grant	:	10 December 2021 (the “ Grant Date ”)
Exercise price of the Share Options granted	:	HK\$3.836 per Share, which represents the highest of: (i) the closing price of HK\$3.800 per Share as stated in the daily quotation sheets issued by the Stock Exchange on the Grant Date, i.e. 10 December 2021;

(ii) the average closing price of HK\$3.836 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five (5) business days immediately preceding the Grant Date;

(iii) the nominal value of a Share.

Number of Share Options granted : 35,000,000 (each Share Option shall entitle the holder thereof to subscribe for one Share)

Validity and exercise period of the Share Options : ten (10) years from the Grant Date with the following exercise periods

(i) First tranche (10% of the Share Options) is exercisable upon completion of the Group's annual performance assessment of 2022;

(ii) Second tranche (15% of the Share Options) is exercisable upon completion of the Group's annual performance assessment of 2023;

(iii) Third tranche (20% of the Share Options) is exercisable upon completion of the Group's annual performance assessment of 2024;

(iv) Fourth tranche (25% of the Share Options) is exercisable upon completion of the Group's annual performance assessment of 2025;

(v) Fifth tranche (30% of the Share Options) is exercisable upon completion of the Group's annual performance assessment of 2026;

The exercise of the Share Options is also subject to the Grantees meeting their respective performance targets as determined by the Company for the respective years as set out above.

None of the Grantees is a Director, chief executive or substantial shareholder of the Company or an associate (as defined in the Listing Rules) of any of them.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 10 December 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors of the Company; Mr. JIANG Feng being non-executive Director of the Company; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Luming and Mr. WANG Wansong being independent non-executive Directors of the Company.